Thrombotic Events and Increased Mortality: Increased mortality was observed in patients randomized to a target hematocrit of 42% [(35% mortality)] compared to patients targeted to remain at a hematocrit of 30% [(29% mortality)].
Chronic Renal Failure Patients: Hypertension: Patients with uncontrolled hypertension should not be treated with erythropoietin; blood pressure should be controlled adequately before initiation of therapy. During the early phase of treatment when the hematocrit is increasing, approximately 25% of patients on dialysis may require initiation of, or increases in, antihypertensive therapy. Hypertensive encephalopathy and seizures have been observed in patients with CRF treated with erythropoietin.
Seizures: Seizures have occurred in patients with CRF participating in erythropoietin clinical trials. It is recommended that the dose of erythropoietin be decreased if the hematocrit increase exceeds 4 points in any 2-week period.
Thrombotic Events: During hemodialysis, patients treated with erythropoietin may require increased anticoagulation with heparin to prevent clotting of the artificial kidney.